Published in Haematologica on July 16, 2009
Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells. Nat Med (2013) 2.39
Quantitatively different red cell/nucleated cell chimerism in patients with long-term, persistent hematopoietic mixed chimerism after bone marrow transplantation for thalassemia major or sickle cell disease. Haematologica (2010) 1.32
Clinical perspectives for regulatory T cells in transplantation tolerance. Semin Immunol (2011) 1.23
The cellular and molecular mechanisms of immuno-suppression by human type 1 regulatory T cells. Front Immunol (2012) 1.23
Antigen-specific dependence of Tr1-cell therapy in preclinical models of islet transplant. Diabetes (2009) 1.08
Functional type 1 regulatory T cells develop regardless of FOXP3 mutations in patients with IPEX syndrome. Eur J Immunol (2011) 1.03
Immunological Outcome in Haploidentical-HSC Transplanted Patients Treated with IL-10-Anergized Donor T Cells. Front Immunol (2014) 1.01
Killing of myeloid APCs via HLA class I, CD2 and CD226 defines a novel mechanism of suppression by human Tr1 cells. Eur J Immunol (2011) 1.00
Enforced IL-10 expression confers type 1 regulatory T cell (Tr1) phenotype and function to human CD4(+) T cells. Mol Ther (2012) 0.93
Molecular and functional characterization of allogantigen-specific anergic T cells suitable for cell therapy. Haematologica (2010) 0.93
Glycoantigens induce human peripheral Tr1 cell differentiation with gut-homing specialization. J Biol Chem (2011) 0.91
Advances on Non-CD4 + Foxp3+ T Regulatory Cells: CD8+, Type 1, and Double Negative T Regulatory Cells in Organ Transplantation. Transplantation (2015) 0.80
Characterization of long-term mixed donor-donor chimerism after double cord blood transplantation. Clin Exp Immunol (2010) 0.80
Naturally acquired microchimerism: implications for transplantation outcome and novel methodologies for detection. Chimerism (2014) 0.80
Regulatory T Cell Immunotherapy in Immune-Mediated Diseases. Curr Stem Cell Rep (2015) 0.78
Mixed chimerism evolution is associated with T regulatory type 1 (Tr1) cells in a β-thalassemic patient after haploidentical haematopoietic stem cell transplantation. Chimerism (2015) 0.76
Peripheral red blood cell split chimerism as a consequence of intramedullary selective apoptosis of recipient red blood cells in a case of sickle cell disease. Mediterr J Hematol Infect Dis (2014) 0.75
3G11 expression in CD4+ T cell-mediated autoimmunity and immune tolerance. Int Immunopharmacol (2010) 0.75
TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol (1989) 31.72
A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature (1997) 16.28
Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev (2006) 10.24
HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med (2008) 7.42
Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev (2006) 6.08
Lymphokine production by human T cells in disease states. Annu Rev Immunol (1994) 4.90
Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans. Nat Rev Immunol (2007) 4.55
Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity (2004) 4.11
Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation. N Engl J Med (2003) 3.57
Type 1 T regulatory cells. Immunol Rev (2001) 3.26
High levels of interleukin 10 production in vivo are associated with tolerance in SCID patients transplanted with HLA mismatched hematopoietic stem cells. J Exp Med (1994) 2.70
Regulatory T cells under scrutiny. Nat Rev Immunol (2003) 2.64
Differential expression of granzymes A and B in human cytotoxic lymphocyte subsets and T regulatory cells. Blood (2004) 2.58
Role of interleukin 10 in specific immunotherapy. J Clin Invest (1998) 2.57
Tr1 cells: from discovery to their clinical application. Semin Immunol (2006) 2.05
Marrow transplantation in patients with thalassemia responsive to iron chelation therapy. N Engl J Med (1993) 2.02
Human allograft acceptance is associated with immune regulation. J Clin Invest (2000) 1.94
Donor/recipient mixed chimerism does not predict graft failure in children with beta-thalassemia given an allogeneic cord blood transplant from an HLA-identical sibling. Haematologica (2008) 1.78
Growth and expansion of human T regulatory type 1 cells are independent from TCR activation but require exogenous cytokines. Eur J Immunol (2002) 1.76
Induction of kidney allograft tolerance after transient lymphohematopoietic chimerism in patients with multiple myeloma and end-stage renal disease. Transplantation (2002) 1.75
Regulatory T cells - a brief history and perspective. Eur J Immunol (2007) 1.70
Quantitative determination of bone marrow transplant engraftment using fluorescent polymerase chain reaction primers for human identity markers. Blood (1995) 1.68
Induction of tolerance in type 1 diabetes via both CD4+CD25+ T regulatory cells and T regulatory type 1 cells. Diabetes (2006) 1.48
Advances in the allogeneic transplantation for thalassemia. Blood Rev (2007) 1.33
High-level long-term white blood cell microchimerism after transfusion of leukoreduced blood components to patients resuscitated after severe traumatic injury. Transfusion (2005) 1.30
Long-term survival of ex-thalassemic patients with persistent mixed chimerism after bone marrow transplantation. Bone Marrow Transplant (2000) 1.29
Intrathymic deletion of alloreactive T cells in mixed bone marrow chimeras prepared with a nonmyeloablative conditioning regimen. Transplantation (1998) 1.25
The cure of thalassemia by bone marrow transplantation. Blood Rev (2002) 1.20
Human CD4+ T lymphocytes with remarkable regulatory functions on dendritic cells and nickel-specific Th1 immune responses. J Invest Dermatol (2000) 1.18
Thymic dependence of loss of tolerance in mixed allogeneic bone marrow chimeras after depletion of donor antigen. Peripheral mechanisms do not contribute to maintenance of tolerance. Transplantation (1996) 1.18
Bone marrow transplantation in adult thalassemic patients. Blood (1999) 1.16
Prognostic significance of increased IL-10 production in patients prior to allogeneic bone marrow transplantation. Bone Marrow Transplant (2000) 1.14
Tolerance in mixed chimerism - a role for regulatory cells? Trends Immunol (2004) 1.06
Clonal regulatory T cells specific for a red blood cell autoantigen in human autoimmune hemolytic anemia. Blood (2007) 1.05
CD4+CD25+ regulatory T cells and graft-versus-host disease. Semin Hematol (2006) 1.04
Bone marrow transplantation in adults with thalassemia: Treatment and long-term follow-up. Ann N Y Acad Sci (2005) 0.99
Interleukin-10-mediated regulatory T-cell responses to epitopes on a human red blood cell autoantigen. Blood (2002) 0.96
Persistence of mixed chimerism in patients transplanted for the treatment of thalassemia. Blood (1996) 0.95
High spontaneous IL-10 production in unrelated bone marrow transplant recipients is associated with fewer transplant-related complications and early deaths. Bone Marrow Transplant (1999) 0.94
The human leucocyte antigen-G 14-basepair polymorphism correlates with graft-versus-host disease in unrelated bone marrow transplantation for thalassaemia. Br J Haematol (2007) 0.91
Early complete donor hematopoietic chimerism in peripheral blood indicates the risk of extensive graft-versus-host disease. Bone Marrow Transplant (2005) 0.90
Mixed chimerism approach to induction of transplant tolerance: a review of the Massachusetts General Hospital experience. Transplant Proc (2007) 0.85
Production of IL-10 by alloreactive sibling donor cells and its influence on the development of acute GVHD. Bone Marrow Transplant (2006) 0.83
Analysis of beta-globin mutations shows stable mixed chimerism in patients with thalassemia after bone marrow transplantation. Blood (1995) 0.82
Immune modulation and microchimerism after unmodified versus leukoreduced allogeneic red blood cell transfusion in cancer patients: results of a randomized study. Transfusion (2007) 0.80
Mixed T-lymphoid chimerism after allogeneic bone marrow transplantation for hematologic malignancies of children is not correlated with relapse. Blood (1993) 0.80
Lineage-specific engraftment and outcomes after T-cell-depleted peripheral blood stem cell transplant with Flu/Cy/TBI conditioning. Br J Haematol (2005) 0.78
Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med (2009) 8.20
Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science (2002) 6.46
Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev (2006) 6.08
Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science (2013) 5.64
Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. Int Immunol (2007) 5.45
Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science (2013) 5.34
Evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas. J Natl Cancer Inst (2004) 4.07
Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. Lancet Oncol (2009) 3.89
The role of 2 FOXP3 isoforms in the generation of human CD4+ Tregs. J Clin Invest (2005) 3.83
Loss of mismatched HLA in leukemia after stem-cell transplantation. N Engl J Med (2009) 3.38
Th17 cells express interleukin-10 receptor and are controlled by Foxp3⁻ and Foxp3+ regulatory CD4+ T cells in an interleukin-10-dependent manner. Immunity (2011) 3.38
Differentiation of Tr1 cells by immature dendritic cells requires IL-10 but not CD25+CD4+ Tr cells. Blood (2004) 2.76
Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapy. J Clin Invest (2007) 2.63
Defective regulatory and effector T cell functions in patients with FOXP3 mutations. J Clin Invest (2006) 2.58
Haploidentical, unmanipulated, G-CSF-primed bone marrow transplantation for patients with high-risk hematologic malignancies. Blood (2012) 2.51
Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells. Nat Med (2013) 2.39
Clinical and molecular profile of a new series of patients with immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome: inconsistent correlation between forkhead box protein 3 expression and disease severity. J Allergy Clin Immunol (2008) 2.18
Regulatory T cells: recommendations to simplify the nomenclature. Nat Immunol (2013) 2.13
Tr1 cells: from discovery to their clinical application. Semin Immunol (2006) 2.05
Suicide gene therapy of graft-versus-host disease induced by central memory human T lymphocytes. Blood (2005) 1.92
Integration of retroviral vectors induces minor changes in the transcriptional activity of T cells from ADA-SCID patients treated with gene therapy. Blood (2009) 1.88
CD4+ T-regulatory cells: toward therapy for human diseases. Immunol Rev (2008) 1.85
The role of IL-10 and TGF-beta in the differentiation and effector function of T regulatory cells. Int Arch Allergy Immunol (2002) 1.84
Immune reconstitution in ADA-SCID after PBL gene therapy and discontinuation of enzyme replacement. Nat Med (2002) 1.80
Nonpermissive HLA-DPB1 disparity is a significant independent risk factor for mortality after unrelated hematopoietic stem cell transplantation. Blood (2009) 1.74
Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. Blood (2011) 1.74
Purified T-depleted, CD34+ peripheral blood and bone marrow cell transplantation from haploidentical mother to child with thalassemia. Blood (2009) 1.71
In vivo administration of lentiviral vectors triggers a type I interferon response that restricts hepatocyte gene transfer and promotes vector clearance. Blood (2007) 1.69
A hypomorphic R229Q Rag2 mouse mutant recapitulates human Omenn syndrome. J Clin Invest (2007) 1.67
Antitumor effects of HSV-TK-engineered donor lymphocytes after allogeneic stem-cell transplantation. Blood (2007) 1.67
Hepatocyte-targeted expression by integrase-defective lentiviral vectors induces antigen-specific tolerance in mice with low genotoxic risk. Hepatology (2011) 1.66
Generation of potent and stable human CD4+ T regulatory cells by activation-independent expression of FOXP3. Mol Ther (2007) 1.64
STAT5-signaling cytokines regulate the expression of FOXP3 in CD4+CD25+ regulatory T cells and CD4+CD25- effector T cells. Int Immunol (2008) 1.58
Activation of the aryl hydrocarbon receptor promotes allograft-specific tolerance through direct and dendritic cell-mediated effects on regulatory T cells. Blood (2008) 1.58
IL-7 and IL-15 allow the generation of suicide gene-modified alloreactive self-renewing central memory human T lymphocytes. Blood (2008) 1.55
A proportion of patients with lymphoma may harbor mutations of the perforin gene. Blood (2005) 1.54
Accumulation of peripheral autoreactive B cells in the absence of functional human regulatory T cells. Blood (2012) 1.53
Immune dysregulation, polyendocrinopathy, enteropathy, x-linked syndrome: a paradigm of immunodeficiency with autoimmunity. Front Immunol (2012) 1.51
New approach for bone marrow transplantation in patients with class 3 thalassemia aged younger than 17 years. Blood (2004) 1.51
A T-cell epitope encoded by a subset of HLA-DPB1 alleles determines nonpermissive mismatches for hematologic stem cell transplantation. Blood (2003) 1.40
Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. Blood (2002) 1.40
Integration profile of retroviral vector in gene therapy treated patients is cell-specific according to gene expression and chromatin conformation of target cell. EMBO Mol Med (2011) 1.39
Mutations in STAT3 and diagnostic guidelines for hyper-IgE syndrome. J Allergy Clin Immunol (2010) 1.36
Cytokine-induced killer cells are terminally differentiated activated CD8 cytotoxic T-EMRA lymphocytes. Exp Hematol (2009) 1.33
Quantitatively different red cell/nucleated cell chimerism in patients with long-term, persistent hematopoietic mixed chimerism after bone marrow transplantation for thalassemia major or sickle cell disease. Haematologica (2010) 1.32
Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA. Cancer Immun (2004) 1.29
Ten years of gene therapy for primary immune deficiencies. Hematology Am Soc Hematol Educ Program (2009) 1.28
Tracking human migrations by the analysis of the distribution of HLA alleles, lineages and haplotypes in closed and open populations. Philos Trans R Soc Lond B Biol Sci (2012) 1.28
Regulated and multiple miRNA and siRNA delivery into primary cells by a lentiviral platform. Mol Ther (2009) 1.25
The cellular and molecular mechanisms of immuno-suppression by human type 1 regulatory T cells. Front Immunol (2012) 1.23
Stability of human rapamycin-expanded CD4+CD25+ T regulatory cells. Haematologica (2011) 1.20
Altered intracellular and extracellular signaling leads to impaired T-cell functions in ADA-SCID patients. Blood (2008) 1.19
Mutation at positively selected positions in the binding site for HLA-C shows that KIR2DL1 is a more refined but less adaptable NK cell receptor than KIR2DL3. J Immunol (2012) 1.19
Alterations in the adenosine metabolism and CD39/CD73 adenosinergic machinery cause loss of Treg cell function and autoimmunity in ADA-deficient SCID. Blood (2011) 1.19
Platelet-lysate-expanded mesenchymal stromal cells as a salvage therapy for severe resistant graft-versus-host disease in a pediatric population. Biol Blood Marrow Transplant (2010) 1.17
Clinical tolerance in allogeneic hematopoietic stem cell transplantation. Immunol Rev (2011) 1.16
Evidence for long-term efficacy and safety of gene therapy for Wiskott-Aldrich syndrome in preclinical models. Mol Ther (2009) 1.15
Tr1 cells and the counter-regulation of immunity: natural mechanisms and therapeutic applications. Curr Top Microbiol Immunol (2014) 1.13
Excretion of the novel polyomaviruses KI and WU in the stool of patients with hematological disorders. J Med Virol (2009) 1.11
Correction of beta-thalassemia major by gene transfer in haematopoietic progenitors of pediatric patients. EMBO Mol Med (2010) 1.10
Stem cell transplantation for hemoglobinopathies. Curr Opin Pediatr (2003) 1.09
Gene therapy for primary immunodeficiencies: Part 2. Curr Opin Immunol (2012) 1.09
Selective engraftment of donor CD4+25high FOXP3-positive T cells in IPEX syndrome after nonmyeloablative hematopoietic stem cell transplantation. Blood (2009) 1.08
Frequency and targeted detection of HLA-DPB1 T cell epitope disparities relevant in unrelated hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2007) 1.07
HLA-G expressing DC-10 and CD4(+) T cells accumulate in human decidua during pregnancy. Hum Immunol (2012) 1.06
Therapeutic applications for hematopoietic stem cell gene transfer. Nat Immunol (2002) 1.06
The Wiskott-Aldrich syndrome protein is required for iNKT cell maturation and function. J Exp Med (2009) 1.06
Reversibility of cirrhosis in patients cured of thalassemia by bone marrow transplantation. Ann Intern Med (2002) 1.06
Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor Perifosine in acute myelogenous leukemia cells. Cancer Res (2008) 1.04
An anti-CD45RO/RB monoclonal antibody modulates T cell responses via induction of apoptosis and generation of regulatory T cells. J Exp Med (2005) 1.04
Ex vivo gene therapy with lentiviral vectors rescues adenosine deaminase (ADA)-deficient mice and corrects their immune and metabolic defects. Blood (2006) 1.04
Functional type 1 regulatory T cells develop regardless of FOXP3 mutations in patients with IPEX syndrome. Eur J Immunol (2011) 1.03